Personalized Dosing Protocols for Peptide Use

Why Responses Vary Between People

The same peptide dose can seem to do a lot for one person and nothing for another. Forum and vendor guides respond by suggesting people adjust doses to their own body and early response. This page describes what those guides say and where the ideas come from.

As of October 2026, no trial has tested weight-based or titrated dosing for research peptides such as ipamorelin and BPC-157. The schedules below are community and vendor practice, not tested protocols. Where an approved drug has label dosing, we show it for contrast. For the reported ranges themselves, see our overview of reported peptide doses.

Factors Affecting Individual Response

Body Composition Factors

Factor	Proposed impact	What's known
Body weight	Higher weight may need higher doses	Trials of CJC-1295 and ipamorelin dosed by body weight; user doses scaled by weight are untested
Body fat %	Affects distribution	Not studied for these peptides
Muscle mass	Affects metabolism	Not studied for these peptides
Age	Receptor sensitivity changes	Natural GH output falls with age; effect on peptide response unmeasured

Metabolic Factors

Factor	Impact	Consideration
Metabolic rate	Affects clearance	Guides say faster metabolism may need more frequent dosing; untested
Insulin sensitivity	GH axis interaction	The tesamorelin label warns about glucose intolerance
Thyroid function	Metabolic regulation	Affects overall response
Cortisol levels	GH interaction	Stress affects response

Lifestyle Factors

Factor	Impact	Notes
Training intensity	Affects recovery needs	Guides say higher training may need more; no data
Sleep quality	Natural GH release	Much of daily GH release happens during sleep
Nutrition	Substrate availability	Protein intake matters
Stress levels	Hormonal environment	Often blamed, rarely measured

Starting Doses in Community Guides

The figures guides start from rarely match the doses used in human studies.

Peptide	Reported by users or vendors	Human study dosing
Ipamorelin	200-300 mcg per dose (vendor guidance); many users take 100-300 mcg at bedtime	IV, by body weight (0.03 mg/kg twice daily in a failed post-surgery Phase 2)
CJC-1295 (no DAC)	100-300 mcg as Mod GRF 1-29 with ipamorelin	DAC form: 30-250 mcg/kg subcutaneously in 2006 studies
BPC-157	250-500 mcg/day	No dose-finding study
AOD-9604 (a modified hGH fragment)	300-500 mcg/day; 300 mcg daily is most common	Oral 0.25-1 mg daily (OPTIONS trial); no injected human data

Some online guides add a weight adjustment, such as extra micrograms for every 20 lb above a set body weight. We couldn't trace any of these formulas to a study or a named source.

Age

Some community guides suggest starting 25-50% lower after 40, on the idea that receptor sensitivity declines with age. We couldn't trace the percentages to a study. The Endocrine Society's 2011 guideline says GH dosing should be individualized, but that covers diagnosed adults on prescription GH, not research peptides.

Prior Experience

Forum guides often tell first-time users to start low and say people with prior performance-enhancing drug (PED) experience tolerate standard amounts. Tolerance to steroids says little about response to a GH secretagogue.

Titration Protocols

For approved drugs, titration schedules come from trials. The Wegovy (semaglutide) label starts at 0.25 mg once weekly and steps up every 4 weeks to a 2.4 mg maintenance dose, mainly to limit gastrointestinal side effects. Tesamorelin, a prescription GHRH analogue, has no titration: the Egrifta WR label sets a fixed 1.28 mg once daily.

Forum guides describe the schedules below for research peptides. None has been tested.

Schedule as described	Weeks 1-2	Weeks 3-4	Later
Standard	50% of target dose	75% of target dose	Full dose from week 5
Faster (described for experienced users)	75% of target in week 1	Full dose	Full dose
Slower (described for older or sensitive users)	25-33% of target	50% of target	75% in weeks 5-6; full dose if tolerated from week 7

The stated reason is to catch side effects such as water retention at a lower dose. Nobody has measured whether this helps with these compounds.

Response Assessment

Subjective Markers

These are self-reported and unblinded, so expectation shapes them.

Marker	Reported timeframe	What users describe
Sleep quality	1-2 weeks	Often improves
Energy levels	2-4 weeks	Mixed reports
Recovery	2-4 weeks	Faster between sessions
Body composition	4-8 weeks	Gradual changes, if any
Mood	Variable	Some report fatigue or low mood early on

Objective Markers

Marker	Testing	What it shows
IGF-1	Blood test at 4-6 weeks	A rise shows a GH-axis effect
Body composition	DEXA or calipers	Lean and fat mass
Strength	Training logs	Gradual improvement, if any
Recovery metrics	HRV, sleep tracking	Rough trend only

The tesamorelin label tells prescribers to monitor IGF-1 during treatment. Our page on blood tests around peptide use covers how results are read.

Response Categories

Forum guides use informal responder labels. The adjustments below are what guides describe, not tested advice.

Response Type	Indicators	Adjustment described in guides
Strong responder	Rapid changes, high IGF-1	May reduce dose
Normal responder	Expected timeline	Maintain protocol
Weak responder	Minimal changes	Consider increasing
Non-responder	No changes after 6-8 weeks	Reassess, consider alternatives

An apparent non-response may also reflect product quality, since gray-market vials vary in content.

How Guides Describe Dose Changes

These figures recur across community guides but trace back to no study.

Indicator	Change described in guides	Notes
Minimal response after 4-6 weeks	Increase 25-50%	Capped at about 2x standard
Side effects present	Reduce 25-50%	Prioritize tolerance
Glucose issues	Reduce or stop	Glucose is the main safety signal
Excellent response on low dose	Stay at low dose	Minimum effective dose

Guides often cite an IGF-1 goal of 200-300 ng/mL and treat values above 350 ng/mL as too high. IGF-1 reference ranges depend on age and lab, so a fixed number means different things at 25 than at 60. The tesamorelin label uses standard deviation scores (SDS) instead, suggesting prescribers consider stopping when IGF-1 stays above about 3 SDS.

The Minimum Effective Dose Idea

Many guides aim for the lowest dose that gives the wanted effect with tolerable side effects. It's a sensible medical principle, but nobody has defined that dose for these peptides.

Timing and Frequency

Users commonly report a main dose of ipamorelin or Mod GRF 1-29 before bed, timed to the overnight GH pulse, on an empty stomach. No study has tested that timing. Ipamorelin's short half-life (about 2 hours in an IV study of 48 healthy men) is why guides describe two or three daily doses.

Personalization and Stacks

Forum guides describe starting with a single peptide, then adding a second at a low dose so new side effects can be traced. No study has tested these stacks. See our page on how users cycle peptides for on/off schedules.

Special Populations

Older Adults (50+)

Guides describe starting at 50-75% of standard with 4 weeks or more between increases. Glucose deserves the closest attention, since GH-raising compounds can reduce insulin sensitivity.

Women

Guides often say women may be more sensitive and that the menstrual cycle may affect response. Neither claim has been studied for these peptides, and there are no human fertility or pregnancy data.

Athletes with High Training Volume

Some guides suggest higher doses for heavy training, without data. As of October 2026, WADA prohibits all four peptides on this page at all times: ipamorelin and CJC-1295 under S2.2.4, AOD-9604 under S2.2.3 and BPC-157 under S0.

Documentation and Tracking

What Users Record

Data Point	Frequency	Purpose
Dose and timing	Each injection	Protocol adherence
Subjective response	Daily/weekly	Trend analysis
Side effects	When occur	Pattern identification
Training performance	Each session	Objective measure
Body measurements	Weekly	Progress tracking

Users who keep logs describe looking for patterns over weeks rather than days and correlating changes with dose adjustments. A personal log can't separate a peptide's effect from training or expectation, so it's weak evidence.

What We Still Don't Know

Whether body weight or age changes the response to any of these peptides in people.
Whether titration reduces side effects for GH secretagogues as it does for semaglutide.
How much apparent non-response comes from product quality rather than biology.